Navigation Links
New hope for hepatitis C sufferers
Date:2/7/2008

Adelaide scientists will lead a $2 million five-year project to develop new vaccines and explore better treatment options for hepatitis C sufferers.

University of Adelaide virologists Dr Michael Beard and Dr Karla Helbig will work with colleagues from the University of NSW to develop new strategies to treat and prevent hepatitis C, which infects more than 170 million people around the world.

The scientists, who are also attached to the Institute of Medical and Veterinary Science and Royal Adelaide Hospital, hope to identify antiviral proteins that can be used in the fight against hepatitis C.

Currently there is no effective vaccine and the existing treatment is expensive and often causes severe side effects. The success rate also varies between 50-80% so many sufferers cannot be helped by current approaches.

The funds, awarded by the National Health and Medical Research Council (NHMRC), are part of a larger $17.7 million joint program grant, tackling both HIV/AIDS and hepatitis C and involving nine scientists from across Australia.

Dr Beard said this was the first Australian program grant awarded to study both HIV/AIDS and HCV/hepatitis C.

The development of vaccines and better treatments for both these viruses are urgent global health priorities, Dr Beard said. This program brings together a team of researchers with skills in basic virology and immunology with experts who can translate laboratory findings into human clinical trials.

This latest grant is an adjunct to three NHMRC project grants awarded to Dr Beards team in the past two years specifically for hepatitis C research.

In 2006 the virologist was awarded more than $894,000 to investigate the link between alcohol and hepatitis C, and the basic mechanisms of liver disease.

In Australia, more than 264,000 people have been infected with the hepatitis C virus and there are approximately 10,000 new infections per year. A proportion of these are intravenous drug users, with alcohol playing a significant role in disease progression, Dr Beard said.

He said vaccines had been trialled for HIV, but with little success. There is antiretroviral treatment but this does not eradicate HIV, it only keeps it under control for a period of time. It is also very expensive and therefore not accessible on a global scale.

Dr Beard said the program would provide a pipeline to develop and test vaccines and novel treatments in a timely fashion.


'/>"/>

Contact: Michael Beard
michael.beard@adelaide.edu.au
61-883-035-522
University of Adelaide
Source:Eurekalert  

Related biology news :

1. Clearance of hepatitis C viral infection after liver transplantation
2. Who will recover spontaneously from hepatitis C virus infection
3. Possible hepatitis C vaccine
4. Eltrombopag effective for hepatitis C patients with low blood-platelet counts
5. Nucleonics initiates hepatitis B clinical trial with expressed interfering RNA therapeutic
6. New Swedish research hope for millions of sufferers
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New hope for hepatitis C sufferers
(Date:4/13/2016)... 2016  IMPOWER physicians supporting Medicaid patients in ... clinical standard in telehealth thanks to a new partnership ... platform, IMPOWER patients can routinely track key health measurements, ... index, and, when they opt in, share them with ... a local retail location at no cost. By leveraging ...
(Date:3/22/2016)... March 22, 2016 ... Sensors Market for Consumer Industry by Type (Image, ... Application (Communication & IT, Entertainment, Home Appliances, ... Forecast to 2022", published by MarketsandMarkets, the ... to reach USD 26.76 Billion by 2022, ...
(Date:3/15/2016)... , March 15, 2016 --> ... published by Transparency Market Research "Digital Door Lock Systems Market ... 2015 - 2023," the global digital door lock systems market ... in 2014 and is forecast to grow at a CAGR ... micro, small and medium enterprises (MSMEs) across the world and ...
Breaking Biology News(10 mins):
(Date:4/29/2016)... Italy , April 29, 2016 ... 5.11, the latest update to its industry-leading treatment planning ... shown that Monaco version 5.11 ... can now attain calculation speeds up to four times ... . With the industry,s gold standard ...
(Date:4/28/2016)... NEW YORK , April 28, 2016 /PRNewswire/ ... biotechnology acceleration company reports the Company,s CEO  was ... capital titled Accelerators Enter When VCs Fear To ... Life Science Leader magazine is an ... work for everything from emerging biotechs to Big ...
(Date:4/28/2016)... ... April 28, 2016 , ... Next week on ... on its first-in-class technologies for tissue stem cell counting and expansion to gene-editing ... to Reprogramming & CRISPR-based Genome Engineering in Burlington, Massachusetts. , The attention of ...
(Date:4/28/2016)... ... 2016 , ... Morris Midwest ( http://www.morrismidwest.com ), a division ... its Maple Grove, Minnesota technical center, May 11-12. The event will feature ... 20 leading suppliers of tooling, accessories, software and other related technology will participate ...
Breaking Biology Technology: